Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.
“The second quarter was one of continued progress, highlighted by steady clinical enrollment in our BDC-1001 monotherapy and combination dose-escalation studies. While we are fortunate to be operating from a position of financial strength, we have implemented a pipeline prioritization and new capital allocation initiative focused on advancing BDC-1001 and BDC-3042, two drug candidates that we believe have high potential to benefit patients,” said Randall C. Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics. “We are winding down spending on BDC-2034, pausing other early-stage research programs, and prioritizing ISAC programs that bring forward the latest generation of our ISAC technology – including our collaboration programs. The combination of these strategic initiatives extends our expected cash runway an additional two years through 2025.”
Dr. Schatzman continued, “We have a lot to look forward to with strong investigator and collaborator interest in our programs, data readouts from the BDC-1001 monotherapy and combination dose-escalation studies on the horizon as well as the advancement of BDC-3042 through IND-enabling activities.”
Recent Business Highlights and Anticipated Milestones
Second Quarter 2022 Financial Results
About the Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) Platform
Bolt Biotherapeutics’ Boltbody ISAC platform unites the precision of antibodies with the power of the innate and adaptive immune system to reprogram the tumor microenvironment for a productive anti-cancer response. Each Boltbody ISAC candidate comprises a tumor-targeting antibody, a non-cleavable linker, and a proprietary immune stimulant. The antibody is designed to target one or more markers on the surface of a tumor cell and the immune stimulant is designed to recruit and activate myeloid cells. Activated myeloid cells initiate a positive feedback loop by releasing cytokines and chemokines, chemical signals that attract other immune cells and lowering the activation threshold for an immune response. This increases the population of activated immune system cells in the tumor microenvironment and promotes a robust immune response, with the goal of generating durable therapeutic responses for patients with cancer.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody and multiple Boltbody ISAC collaboration programs. Bolt Biotherapeutics is currently progressing BDC-1001 through a Phase 1/2 dose-escalation clinical trial, as a monotherapy and in combination with Bristol Myers Squibb’s immune checkpoint inhibitor, Opdivo® (nivolumab), in a variety of HER2-expressing solid tumors. Bolt Biotherapeutics is advancing BDC-3042, an agonist antibody targeting Dectin-2, through IND-enabling studies. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. Bolt Biotherapeutics is leveraging its ability to engineer and optimize novel applications of its Boltbody ISACs to develop multiple immuno-oncology candidates through strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/
Forward-Looking Statements
This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding our clinical trials, the timing of the completion of our monotherapy and combination dose escalation arms and the selection of a recommended Phase 2 dose for BDC-1001 for the treatment of patients with HER2-expressing solid tumors, the timing of our initiation of clinical development of BDC-3042, the resulting ISAC programs from our collaborations with Genmab A/S and Innovent Biologics, Inc., our ability to fund our clinical programs and the sufficiency of our cash, cash equivalents, and marketable securities, our future results of operations, financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing our estimates as of any subsequent date. These statements, and related risks, uncertainties, factors and assumptions, include, but are not limited to: the potential product candidates that we develop may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; such product candidates may not be beneficial to patients or become commercialized; and our ability to maintain our current collaborations and establish further collaborations. These risks are not exhaustive. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2021. These filings, when available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at www.sec.gov.
Opdivo® is a trademark of Bristol-Myers Squibb Company.
BOLT BIOTHERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited, in thousands, except share and per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Collaboration revenue | $ | 1,393 | $ | — | $ | 2,206 | $ | — | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 18,920 | 19,707 | 37,305 | 33,834 | ||||||||||||
| General and administrative | 5,532 | 4,054 | 11,836 | 8,353 | ||||||||||||
| Total operating expense | 24,452 | 23,761 | 49,141 | 42,187 | ||||||||||||
| Loss from operations | (23,059 | ) | (23,761 | ) | (46,935 | ) | (42,187 | ) | ||||||||
| Other income (expense), net | ||||||||||||||||
| Interest income, net | 395 | 176 | 593 | 232 | ||||||||||||
| Change in fair value of preferred stock right liability | — | — | — | (6,084 | ) | |||||||||||
| Total other income (expense), net | 395 | 176 | 593 | (5,852 | ) | |||||||||||
| Net loss | (22,664 | ) | (23,585 | ) | (46,342 | ) | (48,039 | ) | ||||||||
| Net unrealized (loss) gain on marketable securities | (407 | ) | 41 | (1,482 | ) | (23 | ) | |||||||||
| Comprehensive loss | $ | (23,071 | ) | $ | (23,544 | ) | $ | (47,824 | ) | $ | (48,062 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.61 | ) | $ | (0.64 | ) | $ | (1.25 | ) | $ | (1.65 | ) | ||||
| Weighted-average shares outstanding, basic and diluted | 37,293,557 | 36,595,112 | 37,211,174 | 29,088,267 | ||||||||||||
BOLT BIOTHERAPEUTICS, INC.
CONDENSED BALANCE SHEETS
(Unaudited, in thousands)
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 22,618 | $ | 27,383 | ||||
| Short-term investments | 153,717 | 158,836 | ||||||
| Prepaid expenses and other current assets | 4,927 | 2,941 | ||||||
| Total current assets | 181,262 | 189,160 | ||||||
| Property and equipment, net | 6,525 | 6,158 | ||||||
| Operating lease right-of-use assets | 22,607 | 24,445 | ||||||
| Restricted cash | 1,565 | 1,565 | ||||||
| Long-term investments | 47,281 | 85,348 | ||||||
| Other assets | 997 | 1,042 | ||||||
| Total assets | $ | 260,237 | $ | 307,718 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,362 | $ | 3,574 | ||||
| Accrued expenses and other current liabilities | 9,607 | 12,384 | ||||||
| Deferred revenue | 3,508 | 2,869 | ||||||
| Operating lease liabilities | 2,145 | 2,501 | ||||||
| Total current liabilities | 18,622 | 21,328 | ||||||
| Operating lease liabilities, net of current portion | 20,749 | 21,854 | ||||||
| Deferred revenue, non-current | 12,698 | 14,207 | ||||||
| Other long-term liabilities | 200 | 210 | ||||||
| Total liabilities | 52,269 | 57,599 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | — | — | ||||||
| Additional paid-in capital | 463,103 | 457,430 | ||||||
| Accumulated other comprehensive loss | (1,803 | ) | (321 | ) | ||||
| Accumulated deficit | (253,332 | ) | (206,990 | ) | ||||
| Total stockholders' equity: | 207,968 | 250,119 | ||||||
| Total liabilities, convertible preferred stock, and stockholders' equity | $ | 260,237 | $ | 307,718 | ||||
BOLT BIOTHERAPEUTICS, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
| Six Months Ended June 30, | ||||||||
| 2022 | 2021 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (46,342 | ) | $ | (48,039 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 765 | 528 | ||||||
| Stock-based compensation expense | 5,310 | 4,132 | ||||||
| Accretion of premium/discount on marketable securities | 693 | 1,011 | ||||||
| Change in fair value of convertible preferred stock purchase rights liabilities | — | 6,084 | ||||||
| Non-cash lease expense | 1,838 | 1,174 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and other assets | (1,941 | ) | (632 | ) | ||||
| Accounts payable and accrued expenses | (3,087 | ) | 4,110 | |||||
| Operating lease liabilities | (1,461 | ) | (278 | ) | ||||
| Deferred revenue | (870 | ) | 11,363 | |||||
| Other long-term liabilities | (6 | ) | 2 | |||||
| Net cash used in operating activities | (45,101 | ) | (20,545 | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchase of property and equipment | (1,034 | ) | (761 | ) | ||||
| Purchases of marketable securities | (107,433 | ) | (247,768 | ) | ||||
| Maturities of marketable securities | 148,444 | 11,406 | ||||||
| Net cash provided by (used in) investing activities | 39,977 | (237,123 | ) | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of preferred stock, net of issuance cost | — | 51,902 | ||||||
| Proceeds from initial public offering, net of issuance cost | — | 244,316 | ||||||
| Proceeds from issuance of common stock | 359 | 572 | ||||||
| Proceeds from issuance of common stock related to stock purchase agreement | — | 13,638 | ||||||
| Net cash provided by financing activities | 359 | 310,428 | ||||||
| Net (decrease) increase in cash | (4,765 | ) | 52,760 | |||||
| Cash, cash equivalents and restricted cash at beginning of year | 28,948 | 7,107 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 24,183 | $ | 59,867 | ||||
| Reconciliation of cash, cash equivalents and restricted cash: | ||||||||
| Cash and cash equivalents | $ | 22,618 | $ | 58,302 | ||||
| Restricted cash | 1,565 | 1,565 | ||||||
| Total cash, cash equivalents and restricted cash | $ | 24,183 | $ | 59,867 | ||||
| Supplemental schedule of non-cash investing and financing activities: | ||||||||
| Vesting of early exercised options | $ | 4 | $ | 98 | ||||
| Purchases of property and equipment included in accounts payable and accrued liabilities | $ | 98 | $ | 226 | ||||
| Deferred offering costs in accounts payable and accrued liabilities | $ | 102 | $ | — | ||||
| Right of use assets obtained in exchange for operating lease obligations | $ | — | $ | 14,884 | ||||
Investor Relations and Media Contacts:
Karen L. Bergman
Vice President, Communications and Investor Relations
Bolt Biotherapeutics, Inc.
650-665-9295
This email address is being protected from spambots. You need JavaScript enabled to view it.
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
This email address is being protected from spambots. You need JavaScript enabled to view it.
David Schull
Russo Partners, LLC
212-845-4271
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.50 |
| Daily Change: | -0.06 -10.55 |
| Daily Volume: | 81,012 |
| Market Cap: | US$19.140M |
November 12, 2024 November 07, 2024 August 13, 2024 March 21, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
